Head to head
BPC-157 and TB-500 are almost always mentioned together, and suppliers sell a combined vial for that reason. They are not the same molecule and were not developed for the same original purpose, so it is worth separating what each one's evidence actually says before treating them as interchangeable or additive.
BPC-157 is a synthetic pentadecapeptide derived from a partial sequence in human gastric juice, and the evidence base is dominated by rat models of tendon, ligament, muscle and gut injury. TB-500 is marketed as a fragment related to thymosin beta-4, a naturally occurring actin-regulating protein studied for cell migration and tissue repair, and its evidence is similarly dominated by animal and cell culture work.
One controlled rat Achilles tendon study tested a combined BPC-157 plus TB-500 arm against each compound alone. It found no additive benefit over BPC-157 alone, and the ratio tested in that study does not match the ratio in most marketed combination vials. That is the actual evidence behind the popular Wolverine-style blend, and it does not support a stacking advantage.
Neither compound has an approved formulation or a validated human dosing regimen. Both guides on this site classify the evidence as preclinical. Choosing between them on the basis of published human outcomes is not currently possible, because that data does not exist for either one.
Read the full guides
Repair and tissue research
BPC-157 is not FDA approved as a drug and is not the same as any prescription medicine. It is sold by suppliers as a research chemical, and formulations, purity and dosing vary by manufacturer and are not standardized across products.
Read the research →Repair and tissue research
TB-500 as sold commercially is a synthetic peptide marketed as related to thymosin beta-4, not an FDA approved drug. The sources reviewed studied thymosin beta-4 or specific engineered variants such as PEGylated thymosin beta-4, which may differ in structure, purity and pharmacokinetics from a given supplier's TB-500 product.
Read the research →Reign Peptide · Business disclosure
Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.
Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.
Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.